Literature DB >> 20444971

Multicenter study to determine disk diffusion and broth microdilution criteria for prediction of high- and low-level mupirocin resistance in Staphylococcus aureus.

Jana M Swenson1, Betty Wong, Andrew E Simor, Richard B Thomson, Mary Jane Ferraro, Dwight J Hardy, Janet Hindler, James Jorgensen, L Barth Reller, Maria Traczewski, Linda K McDougal, Jean B Patel.   

Abstract

Mupirocin susceptibility testing of Staphylococcus aureus has become more important as mupirocin is used more widely to suppress or eliminate S. aureus colonization and prevent subsequent health care- and community-associated infections. The present multicenter study evaluated two susceptibility testing screening methods to detect mupirocin high-level resistance (HLR), broth microdilution (BMD) MICs of >or=512 microg/ml, and a 6-mm zone diameter for a disk diffusion (DD) test with a 200-microg disk. Initial testing indicated that with Clinical and Laboratory Standards Institute methods for BMD and DD testing, the optimal conditions for the detection of mupirocin HLR were 24 h of incubation and reading of the DD zone diameters with transmitted light. Using the presence or absence of mupA as the "gold standard" for HLR, the sensitivity and specificity of a single-well 256 microg/ml BMD test were 97 and 99%, respectively, and those for the 200-microg disk test were 98 and 99%, respectively. Testing with two disks, 200 microg and 5 microg, was evaluated for its ability to distinguish HLR isolates (MICs >or= 512 microg/ml), low-level-resistant (LLR) isolates (MICs = 8 to 256 microg/ml), and susceptible isolates (MICs <or= 4 microg/ml). Using no zone with both disks as an indication of HLR and no zone with the 5-microg disk plus any zone with the 200-microg disk as LLR, only 3 of the 340 isolates were misclassified, with 3 susceptible isolates being classified as LLR. Use of standardized MIC or disk tests could enable the detection of emerging high- and low-level mupirocin resistance in S. aureus.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20444971      PMCID: PMC2897470          DOI: 10.1128/JCM.00340-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  18 in total

1.  Interpretive criteria for disk diffusion susceptibility testing of mupirocin, a topical antibiotic.

Authors:  P C Fuchs; R N Jones; A L Barry
Journal:  J Clin Microbiol       Date:  1990-03       Impact factor: 5.948

Review 2.  Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA).

Authors:  I Eltringham
Journal:  J Hosp Infect       Date:  1997-01       Impact factor: 3.926

3.  Interpretive criteria for testing susceptibility of staphylococci to mupirocin.

Authors:  J E Finlay; L A Miller; J A Poupard
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

Review 4.  The antimicrobial activity of mupirocin--an update on resistance.

Authors:  B Slocombe; C Perry
Journal:  J Hosp Infect       Date:  1991-09       Impact factor: 3.926

5.  Mutations affecting the Rossman fold of isoleucyl-tRNA synthetase are correlated with low-level mupirocin resistance in Staphylococcus aureus.

Authors:  Martin Antonio; Neil McFerran; Mark J Pallen
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

Review 6.  The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice.

Authors:  B D Cookson
Journal:  J Antimicrob Chemother       Date:  1998-01       Impact factor: 5.790

7.  Improvement of mupirocin E-test for susceptibility testing of Staphylococcus aureus.

Authors:  Pedro Juan José Mondino; Kátia Regina Netto Dos Santos; Maria do Carmo de Freire Bastos; Marcia Giambiagi-deMarval
Journal:  J Med Microbiol       Date:  2003-05       Impact factor: 2.472

8.  Evaluation of disc diffusion and Etest for determining the susceptibility of Staphylococcus aureus to mupirocin.

Authors:  M F Palepou; A P Johnson; B D Cookson; H Beattie; A Charlett; N Woodford
Journal:  J Antimicrob Chemother       Date:  1998-11       Impact factor: 5.790

9.  Mupirocin-resistant, methicillin-resistant Staphylococcus aureus: does mupirocin remain effective?

Authors:  Elaine S Walker; Jose E Vasquez; Roy Dula; Hollie Bullock; Felix A Sarubbi
Journal:  Infect Control Hosp Epidemiol       Date:  2003-05       Impact factor: 3.254

Review 10.  Mupirocin resistance.

Authors:  Jean B Patel; Rachel J Gorwitz; John A Jernigan
Journal:  Clin Infect Dis       Date:  2009-09-15       Impact factor: 9.079

View more
  8 in total

1.  Mupirocin resistance in Staphylococcus aureus causing recurrent skin and soft tissue infections in children.

Authors:  J Chase McNeil; Kristina G Hulten; Sheldon L Kaplan; Edward O Mason
Journal:  Antimicrob Agents Chemother       Date:  2011-01-31       Impact factor: 5.191

Review 2.  Current and Emerging Topical Antibacterials and Antiseptics: Agents, Action, and Resistance Patterns.

Authors:  Deborah A Williamson; Glen P Carter; Benjamin P Howden
Journal:  Clin Microbiol Rev       Date:  2017-07       Impact factor: 26.132

3.  Biographical Feature: Richard B. (Tom) Thomson, Jr., Ph.D., D(ABMM), F(AAM).

Authors:  Erik Munson
Journal:  J Clin Microbiol       Date:  2018-01-24       Impact factor: 5.948

4.  MupB, a new high-level mupirocin resistance mechanism in Staphylococcus aureus.

Authors:  Christine Seah; David C Alexander; Lisa Louie; Andrew Simor; Donald E Low; Jean Longtin; Roberto G Melano
Journal:  Antimicrob Agents Chemother       Date:  2012-01-17       Impact factor: 5.191

5.  Clinical impact of and microbiological risk factors for qacA/B positivity in ICU-acquired ST5-methicillin-resistant SCCmec type II Staphylococcus aureus bacteremia.

Authors:  Haein Kim; Sunghee Park; Hyeonji Seo; Hyemin Chung; Eun Sil Kim; Heungsup Sung; Mi-Na Kim; Seongman Bae; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Yang Soo Kim; Yong Pil Chong
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

6.  Decreased Incidence of Methicillin-Resistant Staphylococcus aureus Bacteremia in Intensive Care Units: a 10-Year Clinical, Microbiological, and Genotypic Analysis in a Tertiary Hospital.

Authors:  Haein Kim; Eun Sil Kim; Seung Cheol Lee; Eunmi Yang; Hee Sueng Kim; Heungsup Sung; Mi-Na Kim; Jiwon Jung; Min Jae Kim; Sung-Han Kim; Sang-Oh Lee; Sang-Ho Choi; Jun Hee Woo; Yang Soo Kim; Yong Pil Chong
Journal:  Antimicrob Agents Chemother       Date:  2020-09-21       Impact factor: 5.191

7.  In vitro activities of LTX-109, a synthetic antimicrobial peptide, against methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, daptomycin-nonsusceptible, and linezolid-nonsusceptible Staphylococcus aureus.

Authors:  Louis D Saravolatz; Joan Pawlak; Leonard Johnson; Hector Bonilla; Louis D Saravolatz; Mohamad G Fakih; Anders Fugelli; Wenche Marie Olsen
Journal:  Antimicrob Agents Chemother       Date:  2012-05-14       Impact factor: 5.191

8.  Mupirocin-resistant Staphylococcus aureus in Africa: a systematic review and meta-analysis.

Authors:  Adebayo O Shittu; Mamadou Kaba; Shima M Abdulgader; Yewande O Ajao; Mujibat O Abiola; Ayodele O Olatimehin
Journal:  Antimicrob Resist Infect Control       Date:  2018-08-15       Impact factor: 4.887

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.